SK pharmteco Plans $200 Million Expansion of Rancho Cordova, California Campus

SK pharmteco announced on September 30 a comprehensive five-year investment plan of more than $200 million to expand and upgrade its U.S. development and manufacturing infrastructure at its Rancho Cordova, California campus. The plan targets growing demand for small molecule APIs and peptide-based medicines.

What the plan includes

• Launch of new development laboratories
• GMP kilo-scale peptide purification capacity, scheduled to be operational in late 2026
• Construction of new manufacturing suites
• Significant investment in utility and sustainability infrastructure

100 high-skilled jobs

The multi-year program is projected to create 100 long-term, high-skilled jobs in California.

Meeting unprecedented demand

Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco, said:

“This commitment to our domestic operations marks a transformative milestone for SK pharmteco. By expanding our domestic capabilities across small molecules and peptides, we are directly addressing unprecedented demand from our broad customer base. Combined with our focus on green technology and modern infrastructure, we are ensuring our customers have a highly reliable, sustainable, and cutting-edge partner from early-stage development through full commercialization.”

— Joerg Ahlgrimm, CEO, SK pharmteco